The future of toll-like receptor therapeutics

Current Opinion in Molecular Therapeutics

Volumn 10, Issue 1, 2008, Pages 21-31

  Parkinson, T ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Allergy; Asthma; Cancer; Infectious disease; Therapy; TLR; Vaccine

Indexed keywords

6 [N (2 CHLORO 4 FLUOROPHENYL)SULFAMOYL] 1 CYCLOHEXENE 1 CARBOXYLIC ACID ETHYL ESTER; 852A; ADJUVANT; AIC; AMPLIGEN; ANA 975; AVE 0675; BCG VACCINE; CADI 05; CPG 10101; CPG 52364; CPG 7909; CPG 9328; CRX 675; ERITORAN; FLAGELLIN; HYB 2125; IC 31; IMIQUIMOD; IMO 2055; IMO 2125; IMOXINE; ISS 1018; LIPOPEPTIDE; OM 174; OM 174 DP; PF 35126; PF 676; PHOSPHORYL LIPID A; RC 529; RESATORVID; RESIQUIMOD; TOLAMBA; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC RHINITIS; ALLERGY; ASTHMA; BLADDER CANCER; BREAST CANCER; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DRUG INDUSTRY; DRUG SAFETY; DRUG STRUCTURE; ENDOMETRIUM CANCER; HEMATOLOGIC DISEASE; HEPATITIS B; HEPATITIS C; HERPES; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION; INFLUENZA; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALARIA; NEOPLASM; NONHODGKIN LYMPHOMA; OVARY CANCER; PROSTATE CANCER; REVIEW; SEPSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL LYMPHOMA; TUBERCULOSIS; UTERINE CERVIX CANCER;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; COMMUNICABLE DISEASES; HUMANS; HYPERSENSITIVITY; NEOPLASMS; TOLL-LIKE RECEPTORS; VACCINES;

EID: 38649123396     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. Yamamoto M, Akira S: Mechanisms of innate immune responses mediated by toll-like receptors. Clin Appl Immunol Rev (2005) 5:167-183. •• An excellent review of TLRs and their role in the innate immune system.
2. Pasare C, Medzhitov R: Toll-like receptors: Linking innate and adaptive immunity. Microb Infect (2004) 6(14):1382-1387.
3. Lemaitre B, Nicolas E, Michaut L, Reichhart J, Hoffmann J: The dorsoventral regulatory gene cassette spatzle/toll/cactus controls the potent antifungal response in Drosophila adults. Cell (1996) 86(6):973-983.
4. Kawai T, Akira S: Pathogen recognition with toll-like receptors. Curr Opin Immunol (2005) 17(4):338-344.
5. 1st launch for 3M's genital warts cream. SCRIP World Pharmaceutical News (1997) 2232:18.
6. Mandal TK: American Academy of Dermatology - 57th Annual Meeting New Orleans, LA, USA. IDDB MEETING REPORT (1999): March 19-24.
7. Meda AB: Meda AB (publ): Year-end report for 2006. Press Release (2007): February 20.
8. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signalling pathway. Nat Immunol (2002) 3(2): 196-200.
9. Wolf IH, Cerroni L, Kodama K, Kerl H: Treatment of lentigo melanoma (melanoma in situ) with the immune response modifier imiquimod. Arch Dermatol (2005) 141(4):510-514.
10. Ray CM, Kluk 10. M, Grin CM, Grant-Kels JM: Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. Int J Dermatol (2005) 44(5):428-434.
11. Witt PL, Ritch PS, Reding D, McAuliffe TL, Westrick L, Grossberg 11. SE, Borden EC: Phase I trial of an oral immunomodulator and interferon inducer in cancer patients. Cancer Res (1993) 53(21):5176-5180.
12. Savage P, Horton V, Moore J, Owens M, Witt P, Gore ME: A phase I clinical trial of imiquimod, an oral interferon inducer, administered daily. Br J Cancer (1996) 74(9):1482-1486.
13. Strominger NL, Brady R, Gullikson G, Carpenter DO: Imiquimodelicited emesis is mediated by the area postrema, but not by direct neuronal activation. Brain Res Bull (2001) 55(3):445-451.
14. Andersen P, Doherty T: Opinion: The success and failure of BCG - implications for a novel tuberculosis vaccine. Nature Rev Microbiol (2005) 3(8):656-662.
15. Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, Hayashi A, Toyoshima K, Seya T: Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin: Involvement of toll-like receptors. Infect Immun (2000) 68(12):6883-6890. • This study demonstrated that BCG acts via TLR2 and TLR4.
16. von Meyenn F, Schaefer M, Weighardt H, Bauer S, Kirschning CJ, Wagner H, Sparwasser T: Toll-like receptor 9 contributes to recognition of Mycobacterium bovis Bacillus Calmette-Guérin by Flt3-ligand generated dendritic cells. Immunobiology (2006) 211(6-8):557- 565.
17. NV Organon: Drug development pipeline: Org-30659, Org-6370, Org-4428, rFSH, Organon, ganirelex, tibolone, mirtazapine, Trimiron, desogestrel, etonogestrel contraceptive implant, Organon, vaginal ring (contraceptive), Organon, Gracial, Org-33408, Org-32818, estradiol implant, Organon, dinoprostone, Organon, pipecuronium, BCG vaccine, Organon, danapariod sodium, SR-90107, rimexolone, Org-5222, Tri-Desogen, estradiol valerate, Orion, Org-12962, rapacuronium bromide. Company Communication (1996): October 10.
18. NCT00525408: A study of Mycobacterium w plus docetaxel for hormone refractory metastatic prostate cancer (HRPC). National Institutes of Health, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ ct2/show/NCT00525408?term=NCT00525408 &rank=1
19. Products in research & development. OM Pharma, Geneva, Switzerland (2007). http://www.ompharma.com/biotech-research/products- research.html
20. Garay RP, Viens P, Bauer J, Normier G, Bardou M, Jeannin JF, Chiavaroli C: Cancer relapse under chemotherapy: Why TLR2/4 receptor agonists can help. Eur J Pharmacol (2007) 563(1-3):1-17.
21. Pink JR, Kieny MP: 4th meeting on novel adjuvants currently in/ close to human clinical testing World Health Organization - organisation Mondiale de la Santé Fondation Mérieux, Annecy, France, 23-25, June 2003. Vaccine (2003) 22(17-18):2097-2102.
22. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, Akira S: A toll-like receptor recognizes bacterial DNA. Nature (2000) 408(6813):740-745.
23. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM: Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol (2004) 34(1):251-262.
24. Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL: Induction of systemic Th1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother (2004) 27(6):460-471.
25. Pfizer Inc: Pfizer to acquire Coley Pharmaceutical Group. Press Release (2007): November 16.
26. Krieg AM: Development of TLR9 agonists for cancer therapy. J Clin Invest (2007) 117(5):1184-1194. • A comprehensive review on the use of TLR9 agonists for the treatment of cancer.
27. Coley Pharmaceutical Group Inc: Coley Pharmaceutical Group's randomized phase II study indicates that CPG 7909 has the potential to improve overall survival when combined with chemotherapy in first-line treatment of advanced non-small cell lung cancer. Press Release (2005): May 14.
28. Coley Pharmaceutical Group Inc: Coley Pharmaceutical Group announces Pfizer's discontinuation of clinical trials for PF-3512676 combined with cytotoxic chemotherapy in advanced non small cell lung cancer. Press Release (2007): June 20.
29. NCT00321308: Trial of pemetrexed with or without PF-3512676 in advanced non-small cell lung cancer. National Institutes of Health, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ct2/show/NCT00321308? term=NCT00321308 &rank=1
30. NCT00321815: Trial of erlotinib with or without PF-3512676 in advanced non small cell lung cancer. National Institutes of Health, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ct2/show/NCT00321815?term=NCT00321815 &rank=1
31. NCT00091208: CpG 7909 in treating patients with cutaneous T-cell lymphoma. National Institutes of Health, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ct2/show/NCT00091208?term=NCT0009120 8&rank=1
32. NCT00369291: CpG 7909 in treating patients who have undergone autologous stem cell transplant. National Institutes of Health, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ct2/show/NCT00369291?term= NCT00369291 &rank=1
33. NCT00185965: Phase I/II CPG 7909 + local XRT in recurrent low-grade lymphomas. National Institutes of Health, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ct2/show/NCT00185965?term=NCT00185965 &rank=1
34. NCT00233506: A dose finding study of CpG in patients with chronic lymphocytic leukemia who have been previously treated. National Institutes of Health, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ct2/show/ NCT00233506?term=NCT00233506 &rank=1
35. Friedberg JW, Kelly J, Kutok JL, Salloum R, Fisher DC, Ronan E, Dalton V, Rich L, Marquis D, Rothberg PG, Liesveld J et al: Combination immunotherapy with a CpG oligonucleotide and rituximab (R) augments the immunological response and favorably alters the malignant microenvironment of follicular lymphoma (FL). Annual Meeting of the American Society of Hematology, Orlando, Fl, USA (2006) 48:891-II.
36. Clinical development programs: Cancer. Dynavax Technologies Corp, Berkeley, CA, USA (2007). http://www.dynavax.com/cancer.htm
37. Hybridon Inc: Hybridon begins phase II trial of anticancer drug. Press Release (2004): October 26.
38. Idera Pharmaceuticals Inc: Idera begins phase I/II cancer trial of TLR-9 agonist. Press Release (2005): October 26.
39. Shakun M, Hwang J, Cotarla I, Sullivan T, Karr R, Marshall J: Initial phase 1 results of gemcitabine, carboplatin and IMO-2055, a toll like receptor 9 (TLR9) agonist, in patients (pts) with advanced solid tumors: P3-112. J Thorac Oncol (2007) 2(8 Suppl 4):S726.
40. Idera Pharmaceuticals Inc: Idera Pharmaceuticals reports financial results for the three months ended March 31, 2007. Press Release (2007): May 15.
41. Pipeline: Oncology. Idera Pharmaceuticals Inc, Cambridge, MA, USA (2007). http://www.iderapharma.com/programs/oncology.php
42. Harrison LI, Astry C, Kumar S, Yunis C: Pharmacokinetics of 852A, an imidazoquinoline toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J Clin Pharm (2007) 47(8):962-969.
43. Coley Pharmaceutical Group Inc: Coley Pharmaceutical Group broadens leading toll-like receptor (TLR) platform through strategic acquisition of 3M company's TLR therapeutic research and development programs. Press Release (2007): June 11.
44. NCT00319748: Study of immune response modifier in the treatment of breast, ovarian, endometrial and cervical cancers. National Institutes of Health, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ct2/show/ NCT00319748?term=NCT00319748 &rank=1
45. NCT00276159: Study of immune response modifier in the treatment of hematologic malignancies. National Institutes of Health, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ct2/show/NCT00276159?term=NCT00276159 &rank=1
46. Barton GM: Viral recognition by toll-like receptors. Semin Immunol (2007) 19(1):33-40.
47. 3M Pharmaceuticals: 3M initiates phase III trials for resiquimod. Press Release (2000): November 03.
48. Eli Lilly & Co; 3M Pharmaceuticals: Preliminary data from recently completed clinical trials of resiquimod suggest dosing used in studies will not achieve adequate efficacy. Press Release (2003): February 24.
49. Pockros PJ, Guyader D, Patton H, Tong MJ, Wright T, McHutchison JG, Meng T-M: Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol (2007) 47(2):174-182.
50. Horsmans Y, Berg T, Desager JP, Mueller T, Schott E, Fletcher SP, Steffy KR, Bauman LA, Kerr BM, Averett DR: Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology (2005) 42(3):724-731.
51. Anadys Pharmaceuticals Inc: Anadys Pharmaceuticals reports first quarter 2006 financial results. Press Release (2006): May 09.
52. Anadys Pharmaceuticals Inc: Anadys suspend ANA-975 dosing in phase I HCV trial. Press Release (2006): June 26.
53. Anadys Pharmaceuticals Inc: Development discontinued for ANA975, an early stage compound for treatment of hepatitis C virus infection. Press Release (2007): July 26.
54. McHutchison JG, Bacon BR, Gordon SC, Lawitz E, Shiffman M, Afdhal NH, Jacobson IM, Muir A, Vicari A, Efler S, Al-Adhami M et al: Final results of a multi-center phase 1b, randomized placebo-controlled, dose escalation trial of CPG10101 in patients with hepatitis C virus. J Hepatol (2006) 44(Suppl 2):S49.
55. Coley Pharmaceutical Group Inc: Coley Pharmaceutical Group updates hepatitis C drug development strategy. Press Release (2007): January 22.
56. Idera Pharmaceuticals Inc: Idera Pharmaceuticals presents preclinical data on IMO-2125 and other TLR9 agonists. Press Release (2007): September 17.
57. Krieg AM: Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc (2007) 4(3):289-294.
58. Tulic MK, Fiset PO, Christodoulopoulos P, Vaillancourt P, Desrosiers M, Lavigne F, Eiden J, Hamid Q: Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol (2004) 113(2):235-241.
59. Development programs: Peanut and cat allergy. Dynavax Technologies Corp (2007). http://www.dynavax.com/allergy.htm
60. Development programs: Asthma/COPD. Dynavax Technologies Corp (2007). http://www.dynavax.com/asthmacopd.htm.
61. Product pipeline: TLR therapeutics™ for asthma and allergy. Coley Pharmaceutical Group Inc, Wellesley, MA, USA (2007). http://www. coleypharma.com/product-pipeline/asthma-allergy.cfm
62. Michel O, Kips J, Duchateau J, Vertongen F, Robert L, Collet H, Pauwels R, Sergysels R: Severity of asthma is related to endotoxin in house dust. Am J Respir Crit Care Med (1996) 154(6 Pt 1):1641-1646.
63. Kaisho T, Hoshino K, Iwabe T, Takeuchi O, Yasui T, Akira S: Endotoxin can induce MyD88-deficient dendritic cells to support Th2 cell differentiation. Int Immunol (2002) 14(7):695-700.
64. Casale TB, Kessler J, Romero FA: Safety of the intranasal toll-like receptor 4 agonist CRX-675 in allergic rhinitis. Ann Allergy Asthma Immunol (2006) 97(4):454-456.
65. Iwasaki A, Medzhitov R: Toll-like receptor control of the adaptive immune responses. Nat Immunol (2004) 5(10):987-995.
66. Spellberg B, Edwards JE Jr: Type 1/type 2 immunity in infectious diseases. Clin Infect Dis (2001) 32(1):76-102.
67. Giannini SL, Hanon E, Moris P, Van Mechelen M, Morel S, Dessy F, Fourneau MA, Colau B, Suzich J, Losonksy G, Martin MT et al: Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine (2006) 24(33-34):5937-5949. • A clinical demonstration that the addition of TLR4 agonist improved the immune response to vaccine.
68. Corixa Corp: GSK's HBV vaccine receives European approval. Press Release (2005): February 08.
69. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, Tyring S, Aoki FY, Slaoui M, Denis M, Vandepapeliere P: Glycoprotein-D- adjuvant vaccine to prevent genital herpes. N Engl J Med (2002) 347(21):1652-1661.
70. Bojang KA, Milligan PJ, Pinder M, Vigneron L, Alloueche A, Kester KE, Ballou WR, Conway DJ, Reece WH, Gothard P, Yamuah L et al: Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in the Gambia: A randomised trial. Lancet (2001) 358(9297):1927-1934.
71. Moutschen M, Léonard P, Sokal EM, Smets F, Haumont M, Mazzu P, Bollen A, Denamur F, Peeters P, Dubin G, Denis M: Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults. Vaccine (2007) 25(24):4697-4705.
72. GlaxoSmithKline plc: GlaxoSmithKline Biologicals and Aeras Global TB Vaccine Foundation partner to develop new TB vaccine. Press Release (2005): October 20.
73. Marchand M, Punt CJ, Aamdal S, Escudier B, Kruit WH, Keilholz U, Håkansson L, van Baren N, Humblet Y, Mulders P, Avril MF et al: Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: A clinical report. Eur J Cancer (2003) 39(1):70-77.
74. Atanackovic D, Altorki NK, Stockert E, Williamson B, Jungbluth AA, Ritter E, Santiago D, Ferrara CA, Matsuo M, Selvakumar A, Dupont B et al: Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients. J Immunol (2004) 172(5):3289-3296.
75. Pajak B, Garze V, Davies G, Bauer J, Moser M, Chiavaroli C: The adjuvant OM-174 induces both the migration and maturation of murine dendritic cells in vivo. Vaccine (2003) 21(9-10):836-842.
76. Meraldi V, Audran R, Romero JF, Brossard V, Bauer J, López JA, Corradin G: OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242-310 from the circumsporozoite protein of Plasmodium berghei. Vaccine (2003) 21(19-20):2485-2491.
77. Speiser DE, Liénard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC, Romero P: Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest (2005) 115(3): 739-746.
78. NCT00344539: AMA1-C1/Alhydrogel + CpG 7909 for malaria. National Institutes of Health, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ ct2/show/NCT00344539?term=NCT00344539 &rank=1
79. Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW, Heathcote J: CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: A double-blind phase I/II study. J Clin Immunol (2004) 24(6):693-701. • A clinical demonstration that addition of a TLR9 agonist improved immunogenicity of the HBV vaccine.
80. Cooper CL, Davis HL, Morris ML, Efler SM, Krieg AM, Li Y, Laframboise C, Al Adhami MJ, Khaliq Y, Seguin I, Cameron DW: Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine (2004) 22(23-24):3136-3143.
81. Halperin SA, Dobson S, McNeil S, Langley JM, Smith B, McCall-Sani R, Levitt D, Nest GV, Gennevois D, Eiden JJ: Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. Vaccine (2006) 24(1):20-26.
82. NCT00435812: Safety and efficacy of Heplisav hepatitis B virus vaccine compared with Engerix-B vaccine. National Institutes of Health, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ct2/show/NCT00435812?term= 1018&cond=h epatitis&phase=2&rank=1
83. Orchestra Therapeutics Inc: Orchestra Therapeutics discontinues its HIV vaccine development program. Press Release (2007): July 17.
84. Lingnau K, Riedl K, von Gabain A: IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems. Expert Rev Vaccines (2007) 6(5):741-746.
85. Ichinohe T, Tamura S, Kawaguchi A, Ninomiya A, Imai M, Itamura S, Odagiri T, Tashiro M, Takahashi H, Sawa H, Mitchell WM et al: Crossprotection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis (2007) 196(9):1313-1320.
86. Shackleton M, Davis ID, Hopkins W, Jackson H, Dimopoulos N, Tai T, Chen Q, Parente P, Jefford M, Masterman KA, Caron D et al: The impact of imiquimod, a toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun (2004) 4:9.
87. Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP: Resiquimod and other immune response modifiers as vaccine adjuvants. Expert Rev Vaccines (2007) 6(5):835-847.
88. Wille-Reece U, Flynn BJ, Loré K, Koup RA, Kedl RM, Mattapallil JJ, Weiss WR, Roederer M, Seder RA: HIV Gag protein conjugated to a tolllike receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates. Proc Natl Acad Sci USA (2005) 102(42):15190-15194.
89. Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA: Immunization with HIV-1 gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 gag-specific Th1 and CD8+ T cell responses. J Immunol (2005) 174(12):7676-7683.
90. Pialoux G, Gahéry-Ségard H, Sermet S, Poncelet H, Fournier S, Gérard L, Tartar A, Gras-Masse H, Levy JP, Guillet JG: Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. AIDS (2001) 15(10):1239-1249.
91. Gahéry-Ségard H, Pialoux G, Charmeteau B, Sermet S, Poncelet H, Raux M, Tartar A, Lévy JP, Gras-Masse H, Guillet JG: Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J Virol (2000) 74(4):1694-1703.
92. VaxInnate Inc: VaxInnate initiates phase I clinical study of M2e universal influenza vaccine. Press Release (2007): September 25.
93. Daftarian P, Sharan R, Haq W, Ali S, Longmate J, Termini J, Diamond DJ: Novel conjugates of epitope fusion peptides with CpG-ODN display enhanced immunogenicity and HIV recognition. Vaccine (2005) 23(26):3453-3468.
94. Klinman DM, Yamshchikov G, Ishigatsubo Y: Contribution of CpG motifs to the immunogenicity of DNA vaccines. J Immunol (1997) 158(8):3635-3639. •• This study demonstrated that adding CpG motifs to DNA vaccines improved immunogenicity.
95. Zhang A, Jin H, Zhang F, Ma Z, Tu Y, Ren Z, Zhang X, Zhu K, Wang B: Effects of multiple copies of CpG on DNA vaccination. DNA Cell Biol (2005) 24(5):292-298.
96. Mao D, Kai G, Gaofu Q, Zheng Z, Li Z, Jie W, Jingjing L, Rongyue C: Intramuscular immunization with a DNA vaccine encoding a 26-amino acid CETP epitope displayed by HBc protein and containing CpG DNA inhibits atherosclerosis in a rabbit model of atherosclerosis. Vaccine (2006) 24(23):4942-4950.
97. Gram GJ, Fomsgaard A, Thorn M, Madsen SM, Glenting J: Immunological analysis of a Lactobacillus lactis-based DNA vaccine expressing HIV gp120. Genet Vaccines Ther (2007) 5:3.
98. Savov JD, Brass DM, Lawson BL, McElvania-Tekippe E, Walker JK, Schwartz DA: Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide. Am J Physiol Lung Cell Mol Physiol (2005) 289(2):L329-L337.
99. Hunter P: Sepsis under siege: A new understanding of sepsis might lead to the development of therapies to treat septic shock. EMBO Rep (2006) 7(7):667-669.
100. No author listed: Eritoran [E5564] reduces 28-day mortality in patients with severe sepsis. Inpharma Weekly (2005) 1503:8.
101. Takeda Pharmaceutical Co Ltd: Takeda's investigational compound (TAK-242) for severe sepsis designated as fast track drugs from the U.S. FDA. Press Release (2005): July 27.
102. Joosten LA, Koenders MI, Smeets RL, Heuvelmans-Jacobs M, Helsen MM, Takeda K, Akira S, Lubberts E, van de Loo FA, van den Berg WB: Toll-like receptor 2 pathway drives Streptococcal cell wall-induced joint inflammation: Critical role of myeloid differentiation factor 88. J Immunol (2003) 171(11):6145-6153.
103. Deng GM, Nilsson IM, Verdrengh M, Collins LV, Tarkowski A: Intraarticularly localized bacterial DNA containing CpG motifs induces arthritis. Nat Med (1999) 5(6):702-705.
104. Kerfoot SM, Long EM, Hickey MJ, Andonegui G, Lapointe BM, Zanardo RC, Bonder C, James WG, Robbins SM, Kubes P: TLR4 contributes to disease-inducing mechanisms resulting in central nervous system autoimmune disease. J Immunol (2004) 173(11):7070-7077.
105. Lang KS, Recher M, Junt T, Navarini AA, Harris NL, Freigang S, Odermatt B, Conrad C, Ittner LM, Bauer S, Luther SA et al: Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med (2005) 11(2):138-145.
106. Marshak-Rothstein A: Toll-like receptors in systemic autoimmune disease. Nat Rev Immuol (2006) 6(11):823-835.
107. Rutz M, Metzger J, Gellert T, Luppa P, Lipford GB, Wagner H, Bauer S: Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol (2004) 34(9):2541-2550.
108. Kyburz D, Brentano F, Gay S: Mode of action of hydroxychloroquine in RA - evidence of an inhibitory effect on toll-like receptor signaling. Nat Clin Pract Rheumatol (2006) 2(9):458-459.
109. NCT00547014: First safety study in humans of a single dose of CPG 52364. National Institutes of Health, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ct2/show/NCT00547014?term=NCT00547014 &rank=1
110. Pipeline: Autoimmune diseases. Idera Pharmaceuticals Inc, Cambridge, MA, USA (2007). http://www.iderapharma.com/programs/autoimmune. php
111. Abreu MT, Fukata M, Arditi M: TLR signalling in the gut in health and disease. J Immunol (2005) 174(8):4453-4460.
112. Bagchi A, Herrup EA, Warren HS, Trigilio J, Shin HS, Valentine C, Hellman J: MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. J Immunol (2007) 178(2):1164- 1171.
113. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S: Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science (2004) 303(5663):1526-1529.
114. Gorden KK, Qiu XX, Binsfeld CC, Vasilakos JP, Alkan SS: Activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides. J Immunol (2006) 177(10):6584- 6587.
115. Manning BM, Enioutina EY, Visic DM, Knudson AD, Daynes RA: CpG DNA functions as an effective adjuvant for the induction of immune responses in aged mice. Exp Gerontol (2001) 37(1): 107-126. •• This study demonstrated that CpG DNA improved vaccine efficacy in the elderly population.
116. Maletto B, Rópolo A, Morón V, Pistoresi-Palencia MC: CpG-DNA stimulates cellular and humoral immunity and promotes Th1 differentiation in aged BALB/c mice. J Leukoc Biol (2002) 72(3):447-454.
117. Alignani D, Maletto B, Liscovsky M, Rópolo A, Morón G, Pistoresi-Palencia MC: Orally administered OVA/CpG-ODN induces specific mucosal and systemic immune response in young and aged mice. J Leukocyte Biol (2005) 77(6):898-905.
118. Sen G, Chen Q, Snapper CM: Immunization of aged mice with a Pneumococcal conjugate vaccine combined with an unmethylated CpG-containing oligodeoxynucleotide restores defective immunoglobulin G antipolysaccharide responses and specific CD4+-T-cell priming to young adult levels. Infect Immun (2006) 74(4):2177-2186.
119. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV: CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med (1997) 186(10):1623-1631.
120. Brazolot Millan CL, Weeratna R, Krieg AM, Siegrist CA, Davis HL: CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci USA (1998) 95(26):15553-15558. •• This study demonstrated that CpG DNA improved vaccine efficacy in neonates.
121. Kovarik J, Bozzotti P, Love-Homan L, Pihlgren M, Davis HL, Lambert PH, Krieg AM, Siegrist CA: CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol (1999) 162(3)1611-1617.
122. Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, Krieg AM, Cameron DW: CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV infected adults. AIDS (2005) 19(14):1473-1479.
123. McCluskie MJ, Weeratna RD: CpG oligodeoxynucleotides as vaccine adjuvants. In: Immunopotentiators in Modern Vaccines. Schijns V, O'Hagan D (Eds), Elsevier Academic Press, San Diego, CA, USA (2006):73-92. • A comprehensive review of the use of CpGs in vaccines.
124. Yang Y, Huang CT, Huang X, Pardoll DM: Persistent toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat Immunol (2004) 5(5):508-515.
125. Peng G, Guo Z, Kiniwa Y, Voo KS, Peng W, Fu T, Wang DY, Li Y, Wang HY, Wang RF: Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science (2005) 309(5739):1380-1384.
126. Ma R, Du JL, Huang J, Wu CY: Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HbsAg vaccination. Biochem Biophys Res Comm (2007) 361(2):537-542.
127. 3M Pharmaceuticals: 3M to partner with Vanguard Medica in evaluating potential treatment of hepatitis C. Press Release (1998): December 11.
128. NCT00537355: An evaluation of the efficacy and safety of Tolamba for ragweed-allergic rhinitis in an environmental exposure chamber. National Institutes of Health, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ ct2/show/NCT00537355?term=NCT00537355 &rank=1
129. NCT00559975: Safety, tolerability, immunogenicity and CPG dosage finding study of Novartis CpG adjuvanted flu vaccine. National Institutes of Health, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ct2/show/ NCT00559975?term=cpg-7909+ and+fluarix&rank=1
130. NCT00076063: A study of LIPO-5 and ALVAC-HIV (vCP1452) as possible HIV vaccines. National Institutes of Health, Bethesda, MD, USA (2007). http://clinicaltrials.gov/ct2/show/NCT00076063?term=lipo-5&rank=1